- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03397251
DARTS I: Feasibility, Safety, and Performance Trial (DARTS I)
Dissected Aorta Repair Through Stent Implantation (DARTS): A Feasibility, Safety and Performance Trial
Study Overview
Status
Intervention / Treatment
Detailed Description
AMDS is designed to complement the replacement of the ascending aorta with conventional surgical technique utilizing a conventional polyester graft. AMDS is constructed of an uncovered Nitinol wire braided stent attached proximally to a polytetrafluoroethylene (PTFE) felt graft component. The PFTE felt graft component excludes the FL at the distal aortic anastomosis and the wire stent re-expands the dissection flap within the arch and descending aorta, which aims to treat malperfusion and promote positive remodeling of the aorta.
The DARTS I Feasibility, Safety and Performance trial is a prospective, non-randomized, non-blinded, single-arm, multi-institutional Canadian study evaluating the feasibility and safety of the AMDS graft. A goal of 30 subjects will be enrolled at 1 site in Germany.
The enrollment period will span a minimum of 3 months from Institutional Review Board (IRB) approval and site activation. Candidates for this study are adults who require repair of an acute DeBakey type I aorta dissection and/or intramural hematoma (IMH). Patients will be consented pre-operatively and enrolled patients will be followed for approximately 5 years after their AMDS implantation date. Data will be collected at 10 time points: baseline (pre-operatively), discharge, 1 month post-operatively, 3 months post-operatively, and 6 months post-operatively, 1 year post-operatively and thereafter, annually, for a total of 5 years.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 13353
- Deutsches Hertzzentrum Berlin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Informed Consent obtained
≥18 years of age or ≤80 years of age (male or female)
Subject must have one of the following diagnosed, based on CT angiography, within 0-14 days:
- Acute DeBakey I dissection or
- Acute DeBakey I intramural hematoma (IMH)
Exclusion Criteria:
General Exclusion Criteria
Patients must be excluded from the study if any of the following conditions are true:
- Less than 18 years of age or over 80 years of age
- Life expectancy less than 2 years
- Pregnant or breastfeeding or planning on becoming pregnant within 60 months
- Unwilling to comply with the follow-up schedule
- Refusal to give informed consent
- Institutionalized individualized due to administrative or judicial order
- Individuals with a dependent relationship to the sponsor or investigator
Medical Exclusion Criteria
Patients must be excluded from the study if any of the following conditions are true:
- Uncontrolled systemic infection
- Uncontrollable anaphylaxis to iodinated contrast
- Known allergy(ies) to Nitinol and/or PTFE
- Patient in extreme hemodynamic compromise requiring cardiopulmonary resuscitation (CPR)
- Inability to obtain CT angiograms for follow-up
- Previously diagnosed with Marfan syndrome, Loeys- Dietz syndrome or Ehlers- Danlos syndrome with confirmed laboratory genetic testing on a date prior to the diagnosis of the dissection
Anatomical Exclusion Criteria
- Any pathology of mycotic origin
- Subacute or chronic dissection of the ascending aorta and aortic arch (>14 days after the index event)
- Aortic fistulous communication with non-vascular structure (e.g. esophagus, bronchial)
- Extensive thrombus or calcifications in the aortic arch as defined by CT angiography
- Excessive tortuosity precluding safe passage of the AMDS as defined by CT angiography
- Descending thoracic aneurysm involving the proximal third (1/3) of the descending aorta and measuring > 45mm in diameter
- Aortic arch aneurysm > 45mm in diameter
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AMDS Implantation
AMDS implantation is performed during an open chest procedure for intervention of aortic dissection repair.
|
The device will be implanted during an already planned surgical intervention for aortic dissection repair.
The participant will be observed and data gathered during the surgery and routine standard of care follow up visits.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with treatment-related mortality
Time Frame: 12 weeks
|
The number of patients with mortality related to the treatment device
|
12 weeks
|
Number of participants with treatment-related neurological deficit
Time Frame: 12 weeks
|
The number of patients with neurological complications related to the treatment device
|
12 weeks
|
Number of patients with aortic injury associated with the implantation of the device
Time Frame: 12 weeks
|
The number of patients with aortic injury related to the treatment device
|
12 weeks
|
Aortic arch branch vessel patency
Time Frame: 12 weeks
|
The number of patients with arch branch vessel stenosis/ occlusion related to the treatment device
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with treatment-related mortality
Time Frame: 24 weeks and 12 months
|
The number of patients with mortality related to the device and procedure
|
24 weeks and 12 months
|
Number of participants with treatment-related neurological deficit
Time Frame: 24 weeks and 12 months
|
The number of patients with neurological complications, such as stroke, TIA, and paralysis/paraplegia) related to the treatment device
|
24 weeks and 12 months
|
Number of patients with aortic injury associated with the implantation of the device
Time Frame: 24 weeks and 12 months
|
The number of patients with aortic injury related to the treatment device
|
24 weeks and 12 months
|
Aortic arch branch vessel patency
Time Frame: 24 weeks and 12 months
|
The number of patients with arch branch vessel stenosis/ occlusion related to the treatment device
|
24 weeks and 12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Re-expansion of the true lumen
Time Frame: 12 weeks, 24 weeks, and 12 months
|
The number of patients with achieved re-expansion of the true lumen following AMDS implantation
|
12 weeks, 24 weeks, and 12 months
|
False lumen reattachment/positive remodeling
Time Frame: 12 weeks, 24 weeks, and 12 months
|
The number of patients which exhibit positive remodeling/false lumen reattachment as measured by CT.
|
12 weeks, 24 weeks, and 12 months
|
False Lumen Thrombosis
Time Frame: 12 weeks, 24 weeks, and 12 months
|
The percentage of patients with evidence of false lumen thrombosis within the confinement of the AMDS, distal to the AMDS but proximal to the Celiac trunk, along the paravisceral aorta and in the infrarenal aorta.
|
12 weeks, 24 weeks, and 12 months
|
Stent-graft integrity Assessment
Time Frame: 12 weeks, 24 weeks, and 12 months
|
The percentage of patients without evidence of stent-graft fractures, kinking, or twisting leading to occlusion or ischemia in patients that have undergone aortic dissection repair with AMDS.
Stent graft integrity will be evaluated by CTA with a Core Imaging Lab.
|
12 weeks, 24 weeks, and 12 months
|
Successful device deployment
Time Frame: 12 weeks, 24 weeks, and 12 months
|
The number of patients which had successful device deployment
|
12 weeks, 24 weeks, and 12 months
|
AMDS removal
Time Frame: 12 weeks, 24 weeks, and 12 months
|
The percentage of patients that required AMDS removal
|
12 weeks, 24 weeks, and 12 months
|
AMDS related re-interventions after the dissection repair
Time Frame: 12 weeks, 24 weeks, and 12 months
|
The percentage of patients with need of secondary intervention related to the AMDS implantation following the index procedure for aortic dissection repair
|
12 weeks, 24 weeks, and 12 months
|
Cardiopulmonary bypass (CBP) duration
Time Frame: 12 weeks, 24 weeks, and 12 months
|
The total time (in minutes) of CBP required for patients undergoing AMDS implantation
|
12 weeks, 24 weeks, and 12 months
|
Circulatory arrest duration
Time Frame: 12 weeks, 24 weeks, and 12 months
|
The total time (in minutes) of circulatory arrest for patients undergoing AMDS implantation
|
12 weeks, 24 weeks, and 12 months
|
Time in ICU
Time Frame: 12 weeks, 24 weeks, and 12 months
|
The total amount of days for patients that have undergo aortic dissection repair with AMDS implantation
|
12 weeks, 24 weeks, and 12 months
|
Duration of hospitalization
Time Frame: 12 weeks, 24 weeks, and 12 months
|
The total number of days of hospitalization required for patients undergoing AMDS implantation
|
12 weeks, 24 weeks, and 12 months
|
AMDS procedure duration
Time Frame: 12 weeks, 24 weeks, and 12 months
|
The total amount of time (in minutes) that it takes for AMDS to be implanted
|
12 weeks, 24 weeks, and 12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jorg Kempfert, MD, German Heart Institute
Publications and helpful links
General Publications
- Bozso SJ, Nagendran J, Chu MWA, Kiaii B, El-Hamamsy I, Ouzounian M, Kempfert J, Starck C, Moon MC. Midterm Outcomes of the Dissected Aorta Repair Through Stent Implantation Trial. Ann Thorac Surg. 2021 Feb;111(2):463-470. doi: 10.1016/j.athoracsur.2020.05.090. Epub 2020 Jul 13.
- Bozso SJ, Nagendran J, Chu MWA, Kiaii B, El-Hamamsy I, Ouzounian M, Kempfert J, Starck C, Shahriari A, Moon MC. Single-Stage Management of Dynamic Malperfusion Using a Novel Arch Remodeling Hybrid Graft. Ann Thorac Surg. 2019 Dec;108(6):1768-1775. doi: 10.1016/j.athoracsur.2019.04.121. Epub 2019 Jun 27.
- Montagner M, Kofler M, Heck R, Buz S, Starck C, Kurz S, Falk V, Kempfert J. Initial experience with the new type A arch dissection stent: restoration of supra-aortic vessel perfusion. Interact Cardiovasc Thorac Surg. 2021 Jul 26;33(2):276-283. doi: 10.1093/icvts/ivab085.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DARTS-AMDS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intramural Hematoma
-
Shenyang Northern HospitalCompletedAortic Intramural Hematoma
-
Guangdong Provincial People's HospitalThe First Affiliated Hospital of Guangzhou Medical University; Shenzhen People... and other collaboratorsRecruitingIntramural HematomaChina
-
Ascyrus Medical LLC.Artivion Inc.Active, not recruiting
-
University of EdinburghNHS Lothian; British Heart FoundationCompletedAortic Dissection | Acute Aortic Syndrome | Penetrating Aortic Ulcer | Intramural HematomaUnited Kingdom
-
Rodney A. White, M.D.RecruitingAortic Dissection | Intramural Hematoma | Penetrating Ulcer | PseudoaneurysmUnited States
-
JOTEC GmbHRecruitingAortic Dissection | Intramural Hematoma | Acute DeBakey I Dissection | Acute Type A DissectionGermany
-
Endospan Ltd.RecruitingAortic Aneurysm | Aortic Dissection | Penetrating Aortic Ulcer | Intramural HematomaUnited States, New Zealand
-
Shanghai MicroPort Endovascular MedTech(Group)Co...Qmed Consulting A/SNot yet recruitingAortic Dissection Type B | Penetrating Aortic Ulcer | Intramural Hematoma
-
Beijing Neurosurgical InstituteRecruitingDissecting Aneurysm of Cerebral Artery | Inflammation Vascular | Intramural HematomasChina
-
China National Center for Cardiovascular DiseasesActive, not recruitingAortic Dissection | Aortic Intramural Hematoma | Aneurysm, Aortic Arch | Aortic Pseudoaneurysm | Aortic Ulcer, PenetratingChina
Clinical Trials on AMDS
-
Ascyrus Medical LLC.Artivion Inc.Active, not recruiting
-
Artivion Inc.Syneos HealthRecruitingAcute Aortic DissectionUnited States
-
JOTEC GmbHRecruitingAortic Dissection | Intramural Hematoma | Acute DeBakey I Dissection | Acute Type A DissectionGermany
-
Chinese University of Hong KongNot yet recruiting